

Attny Docket No. C1190/20007
PTO CUSTOMER NO. 03000

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

(ENTRY INTO U.S. NATIONAL PHASE UNDER CHAPTER II)

International Application No. : PCT/FR99/02682
International Filing Date : November 3, 1999
Priority Date Claimed : FR 98/14033
Filed on November 6, 1998
Title of Invention : PARTICLES COATED WITH GRANULATED
CRYSTALLINE IBUPROFEN
Applicant(s) for DO/EO/US : Jean-Marc ZUCCARELLI
Charles Andre' CHAUVEAU
Gilles DEMICHELIS
Karine JEAN

Box PCT
Commissioner of Patents and Trademarks
Washington, D.C. 20231

Attention: EO/US

Sir:

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This express request to immediately begin national examination procedures (35 U.S.C. 371(f)).

3. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
4. A copy of the International Application as filed (35 U.S.C 371(c)(2)) has been transmitted by the International Bureau. A copy of the cover sheet of international application as published on May 18, 2000, under International Publication No. WO 00/27368 is enclosed.
5. An English translation of International Application No. PCT/FR99/02682 is enclosed.
6. A FIRST preliminary amendment is enclosed.
7. An Abstract is attached to the preliminary amendment.

The Declaration and Assignment will follow at a later date.

BASIC NATIONAL FEE (37 CFR 1.492(1)(1)-(5):

Basic Fee	U.S. PTO was not International Preliminary Examination Authority. Search report on the international application was prepared by the European Patent Office		\$ 860
	Total of above Calculations		\$ 860
	Reduction by 1/2 for filing by small entity	\$	
	Subtotal		\$
	TOTAL NATIONAL FEE		\$ 860

U.S. National Phase of PCT/FR99/14033
Elected Office (EO/US) - page 3 of 4

AUTHORIZATION TO CHARGE ADDITIONAL FEES


The Commissioner is hereby authorized to charge the following additional fees which may be required by this paper and during the entire pendency of this application to counsel's deposit account no. 03-0075:

1. 37 CFR 1.492(a)(1), (2), (3) and (4) (filing fees)
2. 37 CFR 1.492(b), (c) and (d) (presentation of extra claims)
3. 37 CFR 1.17 (application processing fees)
4. 37 CFR 1.492(e) and (f) (surcharge fee for filing declaration and/or filing an English translation of an International Application later than 30 months after the priority date)

This application and items attached are being transmitted before the 30 month claimed priority date.

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN,
COHEN & POKOTILOW, LTD.

By 
Allan H. Fried
Reg. No. 31,253
12th Floor, Seven Penn Center
1635 Market Street
Philadelphia, PA 19103-2212
Attorneys for Applicant

Attorney Docket No. C1190/20007
PTO Customer No. 03000

Applicants : Jean-Marc ZUCCARELLI, et al.
Title : PARTICLES COATED WITH GRANULATED
CRYSTALLINE IBUPROFEN


The following documents are submitted for the above-identified invention for entry into the U.S. National stage under 35 U.S.C. §371, based on the International Application No. PCT/FR99/02682, which includes the following:

1. Two (2) pages of Transmittal Letter to the United States Elected Office (EO/US);
2. Two (2) pages Calculation sheet, in duplicate
3. Cover sheet of International Publication No. WO 00/27368
4. English translation of PCT/FR99/02682
5. A FIRST preliminary amendment, and attached Abstract.
6. Return Receipt Post Card

"Express Mail" Mailing Label No. EL 781 454 670 US
Date of Deposit April 24 2001

I hereby certify that the above-identified documents are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to BOX PCT, Commissioner for Patents, Washington, D.C. 20231, Attention RO/EO/US

Day Karlo



PATENT

Attorney Docket: C1190/20007

PTO CUSTOMER NUMBER: 03000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT EXAMINING OPERATION

Applicants : Jean-Marc ZUCCARELLI, Charles Andre' CHAUVEAU,
Gilles DEMICHELIS, and Karine JEAN

Serial No. : U.S. National Phase of PCT/FR99/02682
filed November 3, 1999

U.S. Filing Date: April 24, 2001

For : PARTICLES COATED WITH GRANULATED
CRYSTALLINE IBUPROFEN

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

IN THE CLAIMS:

Cancel Claims 1-9, without prejudice, and add the following new claims:

-- 10. Coated particles based on granulated microcrystals of ibuprofen, its isomers and its pharmaceutically acceptable salts, wherein they have a coating consisting of a mixture comprising:

- A) from 5 to 50% by weight, preferably from 10 to 30% by weight, of ethyl cellulose, based on the ibuprofen;
- B) from 10 to 60% by weight, preferably 15 to 50% by weight, of hydroxypropyl methyl cellulose, based on ethyl cellulose; and

09/830101-030000

C) from 0.1 to 40% by weight, preferably from 3 to 25% by weight, of silica with antistatic and permeabilizing properties, based on the ethyl cellulose, said coating - of which at least one of the constituents can be used form the granulation of the ibuprofen microcrystals to produce said particles - masking the unpleasant taste of the ibuprofen, significantly reducing its irritant effect on the throat after swallowing, and releasing the ibuprofen substantially immediately when the particles are placed in an aqueous medium.

11. Particles according to Claim 10, having a coating consisting of a mixture comprising:

- A) from 10 to 30% by weight, of ethyl cellulose, based on the ibuprofen;
- B) from 15 to 50% by weight, of hydroxypropyl methyl cellulose, based on the ethyl cellulose; and
- C) from 3 to 25% by weight, of silica with antistatic and permeabilizing properties, based on the ethyl cellulose.

12. Particles according to Claim 10, wherein the silica with antistatic and permeabilizing properties (C) is precipitated silica.

13. Particles according to Claim 10, wherein they also contain an agent (D) favoring the solubilization of the ibuprofen, said agent being selected from the group consisting of mannitol, starch, pharmaceutically acceptable self-emulsifying bases, polyvinylpyrrolidones, stearic macrogol glycerides, alkali metal salts of organic origin, surfactants and mixtures thereof, it also being possible for said agent (D) to be used for the granulation of the crystalline ibuprofen.

14. Particles according to Claim 10, wherein the size distribution of the particles is such that at least 80% of the particles are between 100 and 500 μm and less than 15% of the particles are smaller than 100 μm .

15. Particles according to Claim 10, wherein in a buffer solution of pH 7.2, 80% of the ibuprofen is released in 30 minutes and preferably in 15 minutes.

16. Particles according to Claim 15, wherein in a buffer solution of pH 7.2, 80% of the ibuprofen is released in 15 minutes.

17. Process for the preparation of coated particles based on granulated microcrystals of ibuprofen, its isomers and its pharmaceutically acceptable salts, wherein it comprises, simultaneously or successively, phases consisting in granulating the ibuprofen microcrystals and coating them with a mixture comprising:

- A) 5 to 50% by weight, preferable 10 to 30% by weight, of ethyl cellulose, based on the ibuprofen;
- B) 10 to 60% by weight, preferably 15 to 50% by weight, of hydroxypropyl methyl cellulose, based on the ethyl cellulose; and
- C) 0.1 to 40% by weight, preferably 3 to 25% by weight, of silica with antistatic and permeabilizing properties, based on the ethyl cellulose,

at least one of the constituents of the mixture used for the coating can be used for the granulation of the ibuprofen microcrystals.

18. Process according to Claim 17, wherein the mixture comprises:
- A) 10 to 30% by weight, of ethyl cellulose, based on ibuprofen;
 - B) 15 to 50% by weight, of hydroxypropyl methyl cellulose, based on the ethyl cellulose; and
 - C) 3 to 25% by weight, of silica with antistatic and permeabilizing properties, based on the ethyl cellulose.
19. Process according to Claim 18, wherein the granulation and coating phases take place simultaneously.
20. Process according to Claim 19, wherein it is carried out in a fluidized bed apparatus with an aqueous-alcoholic dispersion under conditions such that the temperature of the ibuprofen is always below 45°C.
21. Process according to Claim 20, wherein it is carried out in a fluidized bed apparatus with an aqueous-alcoholic dispersion under conditions such that the temperature of the ibuprofen is always below 30°C.
22. Process according to Claim 18, wherein in the granulation and/or coating phases, an agent (D) favoring the solubilization of the ibuprofen is also used, said agent being selected from the group consisting of mannitol, starch, pharmaceutically acceptable self-emulsifying bases, polyvinyl-pyrrolidones, stearic macrogol glycerides, alkali metal salts or organic origin, surfactants and mixtures thereof. --

REMARKS

Claims 1-9 have been replaced by Claims 10-22 to eliminate multiple dependency included in the originally filed claims, and to conform the claims with U.S. practice.

The Abstract of the Disclosure is also attached hereto to comply with the requirements of 37 C.F.R. §1.72(b).

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN,
COHEN & POKOTILOW, LTD.

April 24, 2001

By Allan H. Fried
Allan H. Fried
Reg. No. 31,253
12th Floor, Seven Penn Center
1635 Market Street
Philadelphia, PA 19103-2212
Attorneys for Applicant

COATED PARTICLES OF GRANULATED CRYSTALLINE IBUPROFEN

The invention relates to coated particles based on granulated crystalline ibuprofen or its pharmaceutically acceptable salts or esters, which have a coating
5 obtained in a fluidized bed apparatus with an aqueous-alcoholic dispersion, said coating masking the unpleasant taste of the ibuprofen, significantly reducing its irritant effect on the throat after swallowing, and releasing said ibuprofen substantially immediately when the particles reach the gastric medium.

It further relates to the process for the preparation of said particles.

10 The coated particles in question consist of granulated microcrystals of ibuprofen

Patent US 5,215,755 describes tablets in which the ibuprofen is present in the form of granules having a coating based on hydroxyethyl cellulose or a hydroxyethyl cellulose/hydroxypropyl methyl cellulose mixture. This coating
15 affords a better compromise between taste masking and bioavailability, which could not be achieved by the use of ethyl cellulose on its own or mixed with other, already known coating polymers

Patent US 5,814,332 describes ibuprofen particles encapsulated by coacervation of the active principle with cellulosic polymers and gelatin.

20 Patents US 4,835,186 and US 4,835,187 describe ibuprofen powders obtained by a method in which suspensions of colloidal silica in solutions, in organic solvents, of ibuprofen and a cellulosic material such as ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose or cellulose acetophthalate are dried by atomization, said method is better known as nebulization.

25 The object of the invention is to provide novel particles based on crystalline ibuprofen which have a neutral palatability, are tasteless and mask the irritant effect of the active principle. Their particle size distribution and their physical characteristics enable them to be used especially in the manufacture of multiparticulate tablets disintegrating rapidly in the mouth under the action of the
30 saliva, according to patent FR 2679451, and are such that the active principle is released substantially immediately.

As a result of in-depth researches, the Applicant succeeded in discovering that this object was achieved by using a process of granulation and coating in a fluidized bed apparatus with a mixture essentially based on ethyl cellulose,

hydroxypropyl methyl cellulose and silica with antistatic and permeabilizing properties, in defined proportions.

Thus the particles according to the invention, based on granulated microcrystals of ibuprofen, its isomers and its pharmaceutically acceptable salts, are characterized in that they have a coating consisting of a mixture comprising

- A) from 5 to 50% by weight, preferably from 10 to 30% by weight, of ethyl cellulose, based on the ibuprofen,
- B) from 10 to 60% by weight, preferably from 15 to 50% by weight, of hydroxypropyl methyl cellulose, based on the ethyl cellulose, and
- 10 C) from 0.1 to 40% by weight, preferably from 3 to 25% by weight, of silica with antistatic and permeabilizing properties, based on the ethyl cellulose, said coating - of which at least one of the constituents can be used for the granulation of the ibuprofen microcrystals to produce said particles - masking the unpleasant taste of the ibuprofen, significantly reducing its irritant effect on the
- 15 throat after swallowing, and releasing the ibuprofen substantially immediately when the particles are placed in an aqueous medium.

The active principle consists of crystalline ibuprofen or one of its pharmaceutically acceptable salts or esters

The active principle is commercially available in the form of microcrystals with a mean size of between 20 and 80 μm .

The disadvantage of this particle size is that coating by methods which consist in spraying a coating solution onto these microcrystals in a fluidized bed apparatus is difficult and lengthy.

According to the invention, to overcome this disadvantage, the ibuprofen microcrystals are granulated and coated to produce particles whose size is such that at least 80% of the particles are between 100 and 500 μm and less than 15% of the particles are smaller than 100 μm .

In the coated particles according to the invention, the ibuprofen preserves its physicochemical integrity, the intrinsic properties of the active principle being totally unchanged by granulation and coating.

The silica with antistatic and permeabilizing properties (C) can be selected from the group comprising especially colloidal silica, particularly the one marketed under the trade mark AEROSIL[®], and preferably precipitated silica, particularly the one marketed under the trade mark SYLOID[®] FP244, and mixtures thereof.

Advantageously, it is also possible to use an agent (D) which directly or indirectly favours the solubilization of the ibuprofen, said agent being selected from the group comprising especially mannitol, starch, pharmaceutically acceptable self-emulsifying bases, polyvinylpyrrolidones, stearic macrogol glycerides, which are
5 better known as gélucire, alkali metal salts of organic origin such as sodium bicarbonate, surfactants such as sodium laurylsulfate, and mixtures thereof. This agent (D) is present in proportions which can range up to 50% by weight, preferably up to 35% by weight, based on the ibuprofen.

In one advantageous embodiment, the ibuprofen particles are granulated
10 with at least one agent favouring the solubilization of the ibuprofen, said agent preferably being selected from the group comprising stearic macrogol glycerides and hydroxypropyl methyl cellulose, and are coated with an ethyl cellulose/hydroxypropyl methyl cellulose mixture in proportions which make it possible to mask the taste and the irritant effect of the ibuprofen, and with a silica having
15 antistatic and permeabilizing properties, especially precipitated silica, this embodiment optimizing the bioavailability of the ibuprofen.

This achieves a masking of the taste and the irritant effect which is just as satisfactory as with the other method of preparing the particles, but the rate of release of the active principle into aqueous media is optimized.

20 In another advantageous embodiment, the ibuprofen microcrystals are granulated in the presence of microcrystals of an alkali metal salt of organic origin as an agent favouring the solubilization of ibuprofen, and a solution comprising hydroxypropyl methyl cellulose and/or polyvinylpyrrolidone. This alkali metal salt is preferably sodium bicarbonate, which, by dissolving in the gastrointestinal fluids,
25 creates an alkaline micro-pH favouring the solubilization of the ibuprofen particles.

The particles of this constitution are then coated with the coating mixture according to the invention.

In another advantageous embodiment, again in the case where at least one of the constituents of the coating is used for the granulation of the ibuprofen
30 microcrystals, said coating contains an agent favouring solubilization, which can be a soluble agent such as mannitol or a swelling agent such as starch. If a soluble agent is used, it crystallizes on the surface of the ibuprofen particles and, in an acid medium, it solubilizes to leave pores which allow the physiological fluids to enter inside the particle. If a swelling agent is used, a complementary particle bursting

phenomenon takes place.

The particles according to the invention optimize the dissolution of the ibuprofen in aqueous media. The rate of dissolution of the particles is such that, in a buffer solution of pH 7.2, 80% of the ibuprofen is released in 30 minutes and preferably in 15 minutes.

The invention further relates to a process for the preparation of coated particles based on ibuprofen microcrystals. This process comprises, simultaneously or successively, a phase consisting in granulating the ibuprofen microcrystals and a phase consisting in coating them with a coating made up of a mixture of

- 10 A) 5 to 50% by weight, preferably 10 to 30% by weight, of ethyl cellulose, based on the ibuprofen,
- B) 10 to 60% by weight, preferably 15 to 50% by weight, of hydroxypropyl methyl cellulose, based on the ethyl cellulose, and
- C) 0.1 to 40% by weight, preferably 3 to 25% by weight, of silica with antistatic
15 and permeabilizing properties, based on the ethyl cellulose;
- at least one of the constituents of the mixture used for the coating can be used for the granulation of the ibuprofen microcrystals.

In the granulation and/or coating phases, it is also possible to use an agent (D) favouring the solubilization of the ibuprofen, said agent being selected from the group comprising mannitol, starch, pharmaceutically acceptable self-emulsifying bases, polyvinylpyrrolidones, stearic macrogol glycerides, alkali metal salts of organic origin, surfactants and mixtures thereof. In this case said agent (D) is present in proportions which can range up to 50% by weight, preferably up to 35% by weight, based on the ibuprofen.

25 The process according to the invention is carried out in a fluidized bed under temperature conditions such that the temperature of the ibuprofen is always kept below the melting and sublimation points of ibuprofen. In one particular embodiment of the process of the invention, the temperature of the ibuprofen is always kept below 45°C, preferably below 30°C.

30 Because the granulation and coating process used is carried out in a fluidized bed, the ibuprofen is not brought into solution, so it preserves its physicochemical integrity in optimal manner. Furthermore, the use of low temperatures enables any change of state and any risk of degradation of the active principle to be avoided.

In a first embodiment, the granulation and coating phases take place simultaneously by wetting the ibuprofen microcrystals with an aqueous-alcoholic suspension comprising especially ethyl cellulose and hydroxypropyl methyl cellulose and a silica with antistatic and permeabilizing properties

5 In another embodiment of the process according to the invention, the first step, or granulation phase, is carried out using at least one agent favouring solubilization, selected from the group comprising especially stearic macrogol glycerides and hydroxypropyl methyl cellulose, and the second step, or coating phase, is then carried out using a silica with antistatic and permeabilizing properties
10 and a mixture of ethyl cellulose and hydroxypropyl methyl cellulose in proportions which make it possible to mask the taste and the irritant effect of the ibuprofen and to release the ibuprofen substantially immediately.

In another advantageous embodiment of the process according to the invention, in the first step, or granulation step, ibuprofen microparticles are mixed
15 with microcrystals of an alkali metal salt of organic origin as an agent favouring the solubilization of the ibuprofen, and the resulting mixture is granulated with an aqueous-alcoholic dispersion comprising hydroxypropyl methyl cellulose and/or polyvinylpyrrolidone. The coating phase is then carried out with a coating mixture according to the invention.

20

EXAMPLES: Preparation of coated ibuprofen granules

Example 1:

The unit formulation of the coated granules is as follows:

25

Ibuprofen	200.00
Ethyl cellulose N7	40.00
Colloidal silica	3.00
Hydroxypropyl methyl cellulose	8.00
30	251.00 mg

These granules are prepared by the following procedure:

The first step is to prepare a coating dispersion by introducing 24 g of hydroxypropyl methyl cellulose into 390 g of purified water and stirring until the

hydroxypropyl methyl cellulose has completely dissolved. In a separate operation, 9 g of colloidal silica and 120 g of ethyl cellulose N7 are introduced into 110 g of alcohol and the mixture is stirred until a homogeneous dispersion is obtained.

The solution and dispersion obtained above are then mixed, stirring being maintained in order to prevent any sedimentation. A coating dispersion is thus obtained.

The second step is to prepare the coated granules by introducing 600 g of ibuprofen into the cell of a GLATT GPCG1 fluidized bed apparatus and fluidizing the ibuprofen under conditions such that its temperature is kept between 20 and 40°C. The previously prepared coating dispersion is then sprayed onto the bed of ibuprofen obtained above in such a way that the temperature of the product is kept between 15 and 30°C.

50% of the coating dispersion is sprayed for about 1 hour and this is followed by drying for 2 to 5 minutes. The granules obtained are graded on a screen of aperture size 400 µm. The graded granules are then coated with the remaining coating dispersion for approximately 1 h 30 minutes, after which the coated granules are dried for about 5 minutes.

The coated granules contain 79.7% by weight of ibuprofen.

Using a type 4 apparatus described in USP XXIII page 1794, the kinetics of dissolution of the resulting granules are measured in a buffer medium of pH 7.2 with a dissolution volume of 900 ml. The results obtained are indicated below:

Dissolution time in min	Ibuprofen dissolved in %
15	88.1
30	100

Example 2:

The unit formulation of the coated granules is as follows:

Ibuprofen	200.00 mg
Ethyl cellulose N7	40.00 mg
Hydroxypropyl methyl cellulose (HPMC)	8.00 mg
Precipitated silica (Syloid® FP244)	13.70 mg
	261.70 mg

These granules are prepared by the following procedure:

The first step is to prepare a coating dispersion by introducing 24 g of HPMC into 459 g of purified water and stirring until the HPMC has completely dissolved. In a separate operation, 41.9 g of precipitated silica, marketed under the name Syloid® FP244, and 120 g of ethyl cellulose N7 are introduced into 1362 g of alcohol and the mixture is stirred until a homogeneous dispersion is obtained

The solution and dispersion obtained above are then mixed, stirring being maintained in order to prevent any sedimentation. A coating dispersion is thus obtained.

The second step is to prepare the coated granules by introducing 600 g of ibuprofen into the cell of a Glatt GPCG1 fluidized bed apparatus and fluidizing the ibuprofen under conditions such that its temperature is kept between 20°C and 40°C. The previously prepared coating dispersion is then sprayed onto the bed of ibuprofen obtained above in such a way that the temperature of the product is kept between 15°C and 30°C.

50% of the coating dispersion is sprayed for about 1 hour and this is followed by drying for 2 to 5 minutes. The granules obtained are graded on a screen of aperture size 400 µm. The graded granules are then coated with the remaining coating dispersion for approximately one hour thirty minutes, after which the coated granules are dried for about 5 minutes.

The coated granules obtained contain 76.4% by weight of ibuprofen.

Example 3:

The unit formulation of the coated granules is as follows:

Ibuprofen	200.00 mg
Sodium bicarbonate	81.70 mg
Ethyl cellulose	59.90 mg
HPMC	28.60 mg
Colloidal silica	5.50 mg
	375.70 mg

Preparation of the granules:

The first step is to prepare a granulating dispersion by dissolving 50 g of HPMC in 600 ml of purified water and then adding 3 g of colloidal silica, stirring being maintained in order to prevent any sedimentation.

5 The second step is to prepare the granules by introducing 600 g of ibuprofen and 245 g of sodium bicarbonate into the cell of a Glatt GPCG1 fluidized bed apparatus and fluidizing the mixture of powders under conditions such that its temperature is kept between 20°C and 40°C. The previously prepared granulating dispersion is then sprayed onto the bed of powders obtained above in such a way that the temperature of the product is kept between 15°C and 30°C

10 The granulating dispersion is sprayed for about 1 hour 30 minutes and this is followed by drying for 2 to 5 minutes. The granules obtained are graded on a screen of aperture size 500 µm.

Preparation of the coated granules:

15 These granules are prepared by the following procedure:

The first step is to prepare a coating dispersion by introducing 24 g of HPMC into 390 g of purified water and stirring until the HPMC has completely dissolved. In a separate operation, 9 g of colloidal silica and 120 g of ethyl cellulose N7 are introduced into 1160 g of alcohol and the mixture is stirred until a
20 homogeneous dispersion is obtained.

The solution and dispersion obtained above are then mixed, stirring being maintained in order to prevent any sedimentation. A coating dispersion is thus obtained.

25 The second step is to prepare the coated granules by introducing 600 g of ibuprofen granules prepared in the previous step into the cell of a Glatt GPCG1 fluidized bed apparatus and fluidizing the granules under conditions such that their temperature is kept between 20°C and 40°C.

The previously prepared coating dispersion is then sprayed onto the granules in such a way that the temperature of the product is kept between 15°C and 30°C.

30 50% of the coating dispersion is sprayed for about 1 hour and this is followed by drying for 2 to 5 minutes. The granules obtained are graded on a screen of aperture size 500 µm. The graded granules are then coated with the remaining coating dispersion for approximately one hour, after which the coated granules are dried for about 5 minutes.

The coated granules obtained contain 53.1% by weight of ibuprofen.

Example 4:

The unit formulation of the coated granules is as follows:

5	Ibuprofen	200.00 mg
	Corn starch	75.00 mg
	Ethyl cellulose	50.00 mg
	HPMC	10.00 mg
	Colloidal silica	3.50 mg
10		338.50 mg

Preparation of the granules:

The granules are prepared by the following procedure:

- 600 g of ibuprofen and 150 g of corn starch are introduced into a Lödige
 15 bag-type mixer-granulator and granulated with 550 g of purified water. The
 granules obtained are dried in an oven and then graded on a screen of aperture size
 500 μ m.

Preparation of the coated granules:

- 20 These coated granules are prepared by the following procedure:

The first step is to prepare a coating dispersion containing HPMC and corn
 starch by introducing 20 g of HPMC into 333 g of purified water, then stirring until
 the HPMC has completely dissolved, then adding 50 g of corn starch and stirring
 the mixture until a homogeneous dispersion is obtained.

- 25 In a separate operation, 3.5 g of colloidal silica and 100 g of ethyl cellulose
 N7 are introduced into 833 g of alcohol and the mixture is stirred until a
 homogeneous dispersion is obtained.

- The two dispersions obtained above are then mixed, stirring being
 maintained in order to prevent any sedimentation. A coating dispersion is thus
 30 obtained.

The second step is to prepare the coated granules by introducing 500 g of
 ibuprofen granules prepared in the previous step into the cell of a Glatt GPCG1
 fluidized bed apparatus and fluidizing the granules under conditions such that their
 temperature is kept between 20°C and 40°C.

The previously prepared coating dispersion is then sprayed onto the granules in such a way that the temperature of the product is kept between 15°C and 30°C.

5 50% of the coating dispersion is sprayed for about 1 hour and this is followed by drying for 2 to 5 minutes. The granules obtained are graded on a screen of aperture size 500 µm. The graded granules are then coated with the remaining coating dispersion for approximately one hour, after which the coated granules are dried for about 5 minutes.

The coated granules obtained contain 59.1% by weight of ibuprofen.

093610-0300

CLAIMS

1. Coated particles based on granulated microcrystals of ibuprofen, its isomers and its pharmaceutically acceptable salts, characterized in that they have a coating
5 consisting of a mixture comprising
- A) from 5 to 50% by weight, preferably from 10 to 30% by weight, of ethyl cellulose, based on the ibuprofen,
- B) from 10 to 60% by weight, preferably from 15 to 50% by weight, of hydroxypropyl methyl cellulose, based on the ethyl cellulose, and
10 C) from 0.1 to 40% by weight, preferably from 3 to 25% by weight, of silica with antistatic and permeabilizing properties, based on the ethyl cellulose, said coating - of which at least one of the constituents can be used for the granulation of the ibuprofen microcrystals to produce said particles - masking the unpleasant taste of the ibuprofen, significantly reducing its irritant effect on the
15 throat after swallowing, and releasing the ibuprofen substantially immediately when the particles are placed in an aqueous medium.
2. Particles according to Claim 1, characterized in that the silica with antistatic and permeabilizing properties (C) is precipitated silica.
3. Particles according to one of Claims 1 or 2, characterized in that they also
20 contain an agent (D) favouring the solubilization of the ibuprofen, said agent being selected from the group comprising mannitol, starch, pharmaceutically acceptable self-emulsifying bases, polyvinylpyrrolidones, stearic macrogol glycerides, alkali metal salts of organic origin, surfactants and mixtures thereof, it also being possible for said agent (D) to be used for the granulation of the crystalline ibuprofen.
- 25 4. Particles according to one of Claims 1 to 3, characterized in that the size distribution of the particles is such that at least 80% of the particles are between 100 and 500 μm and less than 15% of the particles are smaller than 100 μm .
5. Particles according to one of Claims 1 to 4, characterized in that, in a buffer solution of pH 7.2, 80% of the ibuprofen is released in 30 minutes and preferably in
30 15 minutes.
6. Process for the preparation of coated particles based on granulated microcrystals of ibuprofen, its isomers and its pharmaceutically acceptable salts, characterized in that it comprises, simultaneously or successively, phases consisting in granulating the ibuprofen microcrystals and coating them with a mixture

comprising

- A) 5 to 50% by weight, preferably 10 to 30% by weight, of ethyl cellulose, based on the ibuprofen,
- B) 10 to 60% by weight, preferably 15 to 50% by weight, of hydroxypropyl methyl cellulose, based on the ethyl cellulose, and
- C) 0.1 to 40% by weight, preferably 3 to 25% by weight, of silica with antistatic and permeabilizing properties, based on the ethyl cellulose;

at least one of the constituents of the mixture used for the coating can be used for the granulation of the ibuprofen microcrystals.

- 7. Process according to Claim 6, characterized in that the granulation and coating phases take place simultaneously.
- 8. Process according to Claim 6 or 7, characterized in that it is carried out in a fluidized bed apparatus with an aqueous-alcoholic dispersion under conditions such that the temperature of the ibuprofen is always below 45°C, preferably below 30°C.
- 9. Process according to one of Claims 6 to 8, characterized in that, in the granulation and/or coating phases, an agent (D) favouring the solubilization of the ibuprofen is also used, said agent being selected from the group comprising mannitol, starch, pharmaceutically acceptable self-emulsifying bases, polyvinylpyrrolidones, stearic macrogol glycerides, alkali metal salts of organic origin, surfactants and mixtures thereof.

DECLARATION FOR PATENT APPLICATION

Docket Number (optional) C1190/20007

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PARTICLES COATED WITH GRANULATED CRYSTALLINE IBUPROFEN

the specification of which is attached hereto unless the following box is checked:

Was filed on April 24, 2001 as United States Application Number or PCT International Application Number 09/830,101 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56. I hereby claim foreign priority benefits under 35 U.S.C. §119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365 (a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

FR 98/14033

(Number)

France

(Country)

06 November 1998

(Day/Month/Year Filed)

Priority Claimed

X Yes No Yes No

(Number)

(Country)

(Day/Month/Year Filed)

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

(Application Number)

(Filing Date)

(Application Number)

(Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

PCT/FR99/02682

(Application Number)

03 November 1999

(Filing Date)

Pending

(Status-patented, pending, abandoned)

(Application Number)

(Filing Date)

(Status-patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Alan H. Bernstein (Registration No. 19,315); Stanley H. Cohen (Registration No. 20,235); Manny D. Pokotilow (Registration No. 22,492); Barry A. Stein (Registration No. 25,257); Martin L. Faigus (Registration No. 24,364); Eric S. Marzluf (Registration No. 27,454); Robert S. Silver (Registration No. 35,681); Scott M. Slomowitz (Registration No. 39,032); Michael J. Berkowitz (Registration No. 39,607); David M. Tener (Registration No. 37,054); James J. Kozuch (Registration No. 39,733); Frank M. Linguitti (Registration No. 32,424); Gary A. Greene (Registration No. 38,897); ~~Marilou E. Watson (Registration No. 42,370)~~; Michael J. Cornelison (Registration No. 40,395); ~~Christopher Marrone (Registration No. 46,101)~~; and Allan H. Fried (Registration No. 31,253), care of Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd., 12th Floor, Seven Penn Center, 1635 Market Street, Philadelphia, Pennsylvania 19103-2212, my attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor (given name, family name) Jean-Marc ZuccarelliInventor's signature [Signature]Date 16/08/01 (August)Residence Antibes, FranceCitizenship FrenchPost Office Address Résidence Clos Lamartine, 126 chemin de la Parouquine, 06600 Antibes, FranceFull name of second joint inventor, if any (given name, family name) Charles André ChauveauSecond Inventor's signature [Signature]Date 25/08/01Residence Valbonne, FranceCitizenship FrancePost Office Address 2, ruelle des Bruyères, 06560 Valbonne, France

Additional inventors are being named on separately numbered sheets attached hereto.

Full name of thid inventor (given name, family name) Gilles DeMichelis

Inventor's signature _____

Date 20/08/2020

Residence Grasse, France

Citizenship French

Post Office Address 77, chemin de la tête de lion, St-Jacques, 06130 Grasse, France

Full name of fourth joint inventor, if any (given name, family name) Karine Jean

Second Inventor's signature _____

Date 15/11/01

Residence Cagnes Sur Mer, France

Citizenship France

Post Office Address 12, chemin des Noisetiers, 06800 Cagnes Sur Mer, France[illegible]